# Centene Corporation – Consensus ‘buy’ rating and 26.9% Upside Potential

- Link: https://www.directorstalkinterviews.com/centene-corporation-consensus-buy-rating-and-26.9-upside-potential/4121151767
- Published: 2024-04-16T12:26:48+01:00
- Author: Charlotte Edwards

**Centene Corporation** which can be found using ticker (CNC) have now 15 confirmed
analysts covering the stock with the consensus suggesting a rating of ‘buy’. The
target price High/Low ranges between $110.00 and $76.00 calculating the mean target
price we have $89.73. Given that the stocks previous close was at $70.73 this now
indicates there is a potential upside of 26.9%. Also worth taking note is the 50
day moving average now sits at $76.62 while the 200 day moving average is $71.91.
The total market capitalization for the company now stands at 38.90B. The current
share price for the company is: $72.72 USD

 The potential market cap would be $49,347,522,113 based on the market consensus.

The company has a dividend yield of 1.57%. Other points of data to note are a P/
E ratio of 14.69, revenue per share of $260.01 and a 3.7% return on assets.

Centene Corporation is a healthcare company. The Company provides services to government-
sponsored and commercial healthcare programs, focusing on under-insured and uninsured
individuals. It provides a range of managed healthcare products and services, primarily
through Medicaid, Medicare, and commercial products. Its segments include Medicaid,
Medicare, Commercial and Other. It offers Medicaid and Medicare members (including
Medicare Prescription Drug Plans) as well as individuals and families served by 
the Health Insurance Marketplace and the TRICARE program. It also contracts with
other healthcare and commercial organizations to provide a variety of specialty 
services focused on treating the whole person. Medicaid program provides health 
insurance to low-income families and individuals with disabilities. Medicare is 
a federal health insurance program for people ages 65 and over, which also covers
people under 65 with certain disabilities and people with end-stage renal diseases.

Share on: